Dual Maintenance With BiTE and PD-L1 Inhibitors

Joshua K. Sabari, MD, discusses the anticipated clinical benefits of adding tarlatamab to durvalumab as maintenance therapy for patients with ES-SCLC, highlighting that statistically significant trial end points, such as improved PFS and OS, could encourage community oncologists to adopt this dual maintenance approach.

EP: 1.Clinical Impressions and Therapy Goals

EP: 2.Considerations for Extended Chemoimmunotherapy

EP: 3.Prophylactic Cranial Irradiation Considerations

EP: 4.Mechanism of Action of BiTE Immunotherapy

EP: 5.Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

EP: 6.Significance of Durable Responses in DeLLphi-301 Trial

EP: 7.Expectations for PFS and OS in Relapsed/Refractory SCLC

EP: 8.Future Potential in Combination Therapies

Now Viewing

EP: 9.Dual Maintenance With BiTE and PD-L1 Inhibitors

EP: 10.B7-H3 Mechanism and Therapeutic Potential

EP: 11.Current Practices in B7-H3 Testing

EP: 12.Interpreting IDeate-Lung02 Trial Outcomes

EP: 13.Comparing Dosing Schedules With Standard Therapies

EP: 14.Potential Synergies With T-Cell Engagers

EP: 15.Prospects in First-Line and Maintenance Settings

EP: 16.Mechanism of Action Compared With Other Alkylating Agents

EP: 17.Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC

EP: 18.Comparative Efficacy and Future Directions in SCLC Treatment

Video content above is prompted by the following:

What PFS and OS end points would you typically expect from second- or third-line therapy in your previously treated patients with relapsed/refractory SCLC?

Recent Videos